Joel L. Young, MD: Fibromylagia, Chronic Fatigue, and Adult Attention Deficit Hyperactivity Disorder in the Adult: A Case Study

Name: Joel L. Young, MD: Fibromylagia, Chronic Fatigue, and Adult Attention Deficit Hyperactivity Disorder in the Adult: A Case Study
SKU: 2882
Availability: InStock

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 40 No. 1 Articles Tags: attention-deficit-disorder-with-hyperactivity, chronic, fatigue-syndrome, fibromyalgia, joel-l-young, judith-c-redmond, myofascial-pain-syndromes, pain, psychopharmacology, psychotropic-drugs

Description

Joel L. Young, MD: Fibromylagia, Chronic Fatigue, and Adult Attention Deficit Hyperactivity Disorder in the Adult: A Case Study

Description

Joel L. Young, MD

COMPLICATED CASE HISTORIES

Fibromylagia, Chronic Fatigue, and Adult Attention Deficit Hyperactivity Disorder in the Adult: A Case Study

Joel L. Young, MD and Judith C. Redmond, MA

Alisa B. Busch – Bipolar-I Patient Characteristics Associated with Differences in Antimanic Medication Prescribing

Assessing Rates and Predictors of Tachyphylaxis

Philip T. Ninan, MD: Generalized Anxiety Disorder: Diagnosis, Neurobiology, and Treatment

Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil

Joel L. Young, MD: Fibromylagia, Chronic Fatigue, and Adult Attention Deficit Hyperactivity Disorder in the Adult: A Case Study

Description

Joel L. Young, MD

COMPLICATED CASE HISTORIES

Fibromylagia, Chronic Fatigue, and Adult Attention Deficit Hyperactivity Disorder in the Adult: A Case Study

Joel L. Young, MD and Judith C. Redmond, MA

Related products

Alisa B. Busch – Bipolar-I Patient Characteristics Associated with Differences in Antimanic Medication Prescribing

Assessing Rates and Predictors of Tachyphylaxis

Philip T. Ninan, MD: Generalized Anxiety Disorder: Diagnosis, Neurobiology, and Treatment

Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil